Ignite Creation Date:
2025-12-24 @ 3:15 PM
Ignite Modification Date:
2025-12-26 @ 1:27 AM
Study NCT ID:
NCT06816992
Status:
RECRUITING
Last Update Posted:
2025-03-20
First Post:
2025-02-03
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
ORIC-114 in Combination with Subcutaneous Amivantamab in Patients with EGFR Exon20 Insertion Mutant NSCLC
Sponsor:
ORIC Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-02-27
Start Date Type:
ACTUAL
Primary Completion Date:
2026-05
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-05
Completion Date Type:
ESTIMATED
First Submit Date:
2025-02-03
First Submit QC Date:
None
Study First Post Date:
2025-02-10
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-03-17
Last Update Post Date:
2025-03-20
Last Update Post Date Type:
ACTUAL